In one study, participants using Semaglutide alongside lifestyle changes lost an average of 15% of their body weight over 68 weeks
Why do patients stop a therapy that clearly works
The clinical trial data are applicable globally, but the eligibility criteria shown are based on UK NICE guidelines
A patient carrying a particular GLP1R variant might experience robust appetite suppression at microdose levels, while another individual with a different genetic profile may require standard dosing for the same effect
The Microdose GLP-1Rx program is currently NOT available in Alabama, Arkansas, Iowa, Louisiana, or Mississippi due to state regulations on compounded medications
GLP-1 receptor agonists are medications that mimic this natural hormone